Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640755 | 1.00 | POLB (0.56) | POLBCTBP2L3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL4319346 | 0.88 | CTBP2 (0.51) | POLBCTBP2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL30172792 | 0.88 | CTBP2 (0.51) | POLBCTBP2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL28262488 | 0.88 | POLB (0.54) | POLBCTBP2L3MBTL1CYP1A2 | |
| SCHEMBL2008583 | 0.87 | PPARA (0.57) | L3MBTL1ALDH1A1KDM4EMAPTPPARG | |
| SCHEMBL31285834 | 0.87 | PPARA (0.57) | L3MBTL1ALDH1A1KDM4EMAPTPPARG | |
| SCHEMBL68412 | 0.86 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPTPPARGPPARA | |
| SCHEMBL2096727 | 0.86 | PPARA (0.49) | POLBCTBP2L3MBTL1ALDH1A1PPARG | |
| SCHEMBL21540041 | 0.85 | L3MBTL1 (0.53) | POLBCTBP2L3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL4128970 | 0.85 | PPARA (0.52) | POLBCTBP2L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096420-B | Catalyst for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-109096418-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096420-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096417-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096424-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096421-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024183807-A1 | ARYL FUSED IMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | 哈尔滨三联药业股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| CN-118619885-A | Arylimidazole compound and medical application thereof | 哈尔滨三联药业股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-4279918-A | ANTIDEPRESSANTS, STIMULANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) | 1981-07-21 | — | — | US | disclosed |
| US-4226996-A | 4-SUBSTITUTED-6-OXA-1-AZATRICYCLO/4.2.2.0.2.7/DODECAN-5-ONE SALT | THE PURDUE FREDERICK COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4221788-A | 2-(Optionally-substituted)benzylperhydroazepines for analgesia and lowering blood pressure | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4183938-A | 1,8-Ethano-5-oxo-octa- and -decahydroquinolines and mydriatic compositions thereof | THE PURDUE FREDERICK COMPANY (US) | 1980-01-15 | — | — | US | disclosed |
| US-4083985-A | 6-Oxa-1-aza tricyclo dodecan-5-ones as psychomotor stimulators | THE PURDUE FREDERICK COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4042707-A | ANALGESICS, NARCOTIC ANTAGONISTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-3940486-A | Imidazole derivatives in the treatment of pain | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | POLB 3530/4885CTBP2 4476/4885L3MBTL1 1852/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | POLB 1082/4885CTBP2 158/4885L3MBTL1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.